Your Health, We Care
Alpelisib is the world's first approved PI3K inhibitor for the treatment of solid tumors, developed by Novartis.
There are multiple clinical studies underway internationally on Alpelisib, aimed at further exploring its efficacy and safety in different diseases. These studies include but are not limited to PROS and breast cancer.
Alpelisib is a drug for the treatment of HR/HER2- breast cancer, especially for patients with PIK3CA mutations; Inhibits tumor proliferation by blocking the PI3K pathway.How much d···【more】
Article source：Lucius LaosRelease date：2024-08-22Recommended：131
Alpelisib for the treatment of PIK3CA-mutated HR/HER2- advanced breast cancer in combination with fulvestrant; It is the first drug to target PIK3CA mutations, which can effectivel···【more】
Article source：Lucius LaosRelease date：2024-08-22Recommended：132
Alpelisib, approved in combination with fulvestrant in 2019 for the treatment of HR/HER2- breast cancer, specifically PIK3CA mutation cases; By inhibiting the PI3K pathway, it can ···【more】
Article source：Lucius LaosRelease date：2024-08-22Recommended：120
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
